Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Kisspeptin-1010 residuesYNWNSFGLRFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: KP10, KP-10, Metastin 45-54
A single subcutaneous injection raises luteinizing hormone within 20 minutes. Kisspeptin-10 is the smallest active fragment of kisspeptin, the peptide that tells your hypothalamus to turn on the reproductive hormone cascade. It binds KISS1R on GnRH neurons, triggering a pulsatile release of LH and FSH from the pituitary. The catch: a plasma half-life around 4 minutes IV (closer to 30 minutes subcutaneous) and documented receptor tachyphylaxis with daily use. Fertility clinics are studying it as a safer IVF trigger. The bodybuilding and TRT recovery community uses it to restart endogenous testosterone production without suppressing the HPG axis.
Twenty minutes after injection, serum LH starts climbing. That speed is what makes kisspeptin-10 (KP10, amino acids 112 to 121 of the KISS1 gene product, MW ~1,267 Da) unusual among reproductive peptides. It sits at the very top of the HPG axis, binding the KISS1R (GPR54) receptor on GnRH neurons to trigger downstream gonadotropin release. Published data from Dhillo and colleagues (J Clin Endocrinol Metab 2011)[1] confirmed that a single IV bolus of kisspeptin-10 in healthy men increased LH pulse frequency and amplitude, with testosterone rising measurably afterward. A separate study [2] demonstrated sexual dimorphism in the response; women showed the strongest LH surge during the preovulatory phase. George and colleagues [3] extended this to men with type 2 diabetes and hypogonadism, where kisspeptin-10 still produced an acute LH rise. In practice, the community uses it primarily for two things: natural testosterone optimization and post-TRT HPTA restart. The typical protocol is 100 to 125 mcg subcutaneous nightly, cycled 30 days on and 30 days off. Forum presence is thin compared to BPC-157 or TB-500 but concentrated in specialist boards like ExcelMale. The honest limitation: no large randomized controlled trial has tested kisspeptin-10 for therapeutic hypogonadism. Post-TRT recovery application is biologically plausible but formally unstudied. Continuous dosing causes receptor desensitization [4], and the peptide itself degrades faster than almost anything else on the market, with an in vitro plasma half-life of roughly 55 seconds.
Kisspeptin-10 is the minimal bioactive fragment of the KISS1 gene product. It binds with high affinity to KISS1R (GPR54), a G-protein coupled receptor sitting on GnRH neurons in the arcuate and anteroventral periventricular nuclei of the hypothalamus. Receptor activation triggers Gq/11 signaling. Intracellular calcium rises, protein kinase C activates, and the GnRH neuron depolarizes. The result is pulsatile GnRH secretion into the hypophyseal portal system at the median eminence, a region that lacks a complete blood-brain barrier. GnRH then hits gonadotroph cells in the anterior pituitary, releasing both LH and FSH. The LH pulse following a kisspeptin-10 bolus peaks at 30 to 40 minutes and returns to baseline within roughly 3 hours. In men, that LH spike drives Leydig cell testosterone production. In women, the magnitude depends on menstrual cycle phase; preovulatory timing produces the largest response. One detail that matters for long-term protocols: kisspeptin neurons also integrate metabolic signals from leptin, insulin, and ghrelin, plus photoperiod cues. They function as a gatekeeping node that couples energy status to reproductive output. Repeated or continuous exposure leads to GnRH neuron desensitization and reduced gonadotropin output. That property is actually being explored for endometriosis and precocious puberty, where suppression of the reproductive axis is the goal.
KP10 robustly stimulates LH and FSH release in healthy men and women via KISS1R → GnRH → pituitary axis. Proof-of-concept in T2DM hypogonadism [3]. Blunted response in severe iHH patients. Continuous daily dosing causes documented receptor tachyphylaxis [4]. Intranasal route validated 2025. No FDA-approved therapeutic indication; compounding rejected Oct 2024.
PMID 21632807: KP10 IV bolus increased LH pulse frequency and amplitude in healthy men; testosterone rose significantly (J Clin Endocrinol Metab 2011)
No large RCTs for therapeutic hypogonadism endpoints. Post-TRT recovery application is community-only, not formally studied. Dose–response curve inverts at >3 nmol/kg IV. SC bioavailability estimated but not precisely characterized. iHH patients show blunted response vs. healthy controls.
Used primarily for post-TRT HPTA restart and natural testosterone optimization. Regarded as a clean LH stimulator that does not suppress endogenous production. Consistent complaints: variable individual response, short half-life requiring precise timing, and confusion with kisspeptin-54.
Science confirms robust acute LH stimulation and tachyphylaxis risk. Community application for post-TRT recovery is biologically plausible but not formally studied. Dose ranges are broadly consistent. Community underweights tachyphylaxis risk and cycling necessity more than science recommends.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 400mcg | Daily |
The math on this one matters. A 5 mg vial reconstituted with 2 mL bacteriostatic water gives you 2,500 mcg per mL, or 2.5 mcg per unit on a U-100 insulin syringe. For a 100 mcg dose, you're pulling 4 units. For 125 mcg, pull 5 units. Use BAC water specifically. Sterile water lacks the benzyl alcohol preservative, and given how fast kisspeptin-10 degrades, you want every stability advantage. Plan to use the reconstituted vial within 7 to 10 days, maybe 14 at the outside. Refrigerate immediately after mixing. Timing matters more than usual here. The subcutaneous half-life is only about 30 minutes, so inconsistent injection timing will give you inconsistent LH pulses. Most community protocols call for evening dosing, 60 to 90 minutes before bed, at the same time each day. Don't skip the day-7 LH blood draw (30 to 60 minutes post-injection). It tells you whether your vial is active and your receptors are responding.
Due to potential tachyphylaxis with continuous dosing, pulsatile or intermittent protocols are preferred. Some researchers use twice-daily injections for 1-2 weeks followed by a washout. Monitor LH and testosterone to assess ongoing responsiveness.
Continuous daily kisspeptin-10 exposure causes KISS1R (GPR54) downregulation on GnRH neurons. PMID 19820030 documented tachyphylaxis with daily kisspeptin-54 in women with hypothalamic amenorrhea: LH response diminished significantly with uninterrupted dosing. KP10 shares the same receptor and is subject to the same mechanism. Pulsatile or intermittent protocols (30 on/30 off; or 5 days on/2 days off) preserve receptor sensitivity and sustained efficacy over multi-month use.
Or use the universal Peptide Calculator for any peptide.
Expected: Increased LH pulse frequency and amplitude within days 1–7; testosterone rise measurable by week 2–3. Response magnitude is highly individual.
Monitor: LH at day 7 (30–60 min post-injection) and day 28; total testosterone at day 28
Gather supplies: 5 mg kisspeptin-10 vial, 2 mL bacteriostatic water, alcohol swabs, U-100 insulin syringe (28 to 31 gauge, 0.5 inch needle).
Reconstitute by injecting 2 mL BAC water slowly down the inside wall of the vial. Do not shake. Swirl gently until dissolved. This gives 2,500 mcg/mL (2.5 mcg per unit on a U-100 syringe).
For 100 mcg, draw 4 units. For 125 mcg, draw 5 units. For 200 mcg, draw 8 units. For 300 mcg, draw 12 units.
Preferred sites: abdominal fat (2 inches from the navel) or anterior thigh. Rotate sites daily.
Pinch the skin and insert the needle at a 45 to 90 degree angle. Inject slowly. Hold for 5 seconds before withdrawing.
Timing: inject in the evening, 60 to 90 minutes before bed, at the same time each day. Consistency matters given the 30 minute subcutaneous half-life.
Store the reconstituted vial refrigerated at 2 to 8 degrees Celsius. Use within 7 to 14 days. Do not freeze reconstituted peptide.
On day 7, get a blood draw for LH at 30 to 60 minutes post-injection to confirm your individual response. Total testosterone at day 14 and day 28 tracks the downstream effect.
SC extends effective duration to ~30 min vs. ~4 min IV due to slower depot absorption. Community dose 100–200 mcg/day derived from IV clinical data corrected for estimated SC bioavailability (~60–80%).
Rotate sites (abdomen, anterior thigh). Use 28–31 gauge, 0.5-inch needle.
12.8 nmol/kg intranasal produced mean LH +4.4 IU/L in healthy men and hypothalamic amenorrhea patients (eBioMedicine 2025). No SC-to-intranasal conversion established; direct dose comparison not available.
First non-invasive route with robust confirmed LH stimulation in humans. Requires specific nasal spray formulation (stable 60 days refrigerated in published protocol). Not achievable with standard peptide reconstitution. Monitor for commercial or compounding development.
IV doses in clinical trials: 0.3–3 nmol/kg bolus. Dose–response inverts above ~3 nmol/kg IV (PMID 21632807). Provides immediate peak kinetics; extremely short duration (~4 min half-life).
Reserved for diagnostic testing and clinical research. Self-IV carries unacceptable infection and dosing-error risk.
Sequential HPG axis coverage: KP10 stimulates hypothalamic GnRH neurons; gonadorelin (synthetic GnRH) stimulates pituitary gonadotrophs. Used in post-TRT restart for two-level axis stimulation simultaneously.
100 mcg KP10 + 100 mcg gonadorelin SC daily, same window or staggered 30 min apart
Three-level PCT stack: KP10 (hypothalamus) + HCG (direct Leydig cell stimulation bypassing hypothalamus and pituitary). Covers all three HPG axis levels. Community commonly pairs these during post-TRT recovery.
KP10 100–150 mcg SC daily + HCG 500–1000 IU SC 2–3×/week; monitor testosterone to avoid over-stimulation
GnRH antagonists block pituitary GnRH receptors, abolishing the downstream LH response that KP10 depends on. Concurrent use renders kisspeptin-10 pharmacologically inert.
Do not combineContinuous GnRH agonist exposure causes pituitary desensitization. Concurrent KP10 will produce unpredictable and likely suppressed gonadotropin responses.
Do not combineNot dangerous to combine, but mechanistically redundant for libido purposes and from different pharmacological timescales. PT-141 gives rapid CNS arousal (minutes); KP10 provides slow hormonal axis effects (weeks). May cause additive nausea and flushing.
Pricing updated 2026-04-09
The most important safety concern with kisspeptin-10 is receptor desensitization. A study by Jayasena and colleagues [4] documented tachyphylaxis with daily kisspeptin-54 administration in women with hypothalamic amenorrhea. LH response diminished with uninterrupted dosing. Kisspeptin-10 shares the same KISS1R receptor and is subject to the same mechanism. This is not a mild inconvenience; it can render the peptide pharmacologically useless if cycling protocols are not followed. The second concern is specific to product quality. Kisspeptin-10 has an in vitro plasma half-life of approximately 55 seconds, destroyed by matrix metalloproteinases. It is one of the most degradation-prone peptides available. A vial shipped without cold-chain integrity, reconstituted too early, or stored beyond 2 weeks may contain little to no active peptide. The FDA Pharmacy Compounding Advisory Committee rejected kisspeptin for compounding in October 2024, so all current supply comes from research chemical vendors with variable quality control. Published clinical side effects from controlled studies include headache, nausea, and hot flushes. These appear dose-related and are reported at higher IV doses. At community subcutaneous doses of 100 to 200 mcg daily, user reports of adverse effects are sparse. The community sample size is low, concentrated on specialist boards rather than mainstream peptide forums. One interaction worth flagging: opioid analgesics suppress kisspeptin neuron activity. Chronic opioid use may reduce responsiveness to kisspeptin-10, and opioid-induced hypogonadism already impairs the HPG axis at multiple levels. For hormone-sensitive cancers (breast, prostate, ovarian), acute gonadotropin stimulation from kisspeptin-10 may temporarily spike sex steroid levels. This is a contraindication, not a theoretical concern. Pregnancy is a clear contraindication. Kisspeptin stimulates gonadotropin release that could disrupt early pregnancy hormone balance. Safety in pregnant women has not been studied. Anyone using kisspeptin-10 should stop and consult a physician if persistent headache or nausea develops, if no measurable LH response appears after 14 days of consistent dosing, or if symptoms suggest hormonal excess (gynecomastia, acne flares, mood instability).
Verify Kisspeptin-10 dosing and safety with a second opinion
KP10 is one of the most degradation-prone research peptides: in vitro plasma half-life ~55 seconds, enzymatically destroyed by matrix metalloproteinases. The research chemical market is thin: few vendors, limited third-party HPLC/MS testing. No compounding pharmacy access (FDA PCAC rejected Oct 2024). Quality depends entirely on vendor COA and cold-chain integrity.
| Test | When | Target |
|---|---|---|
| Serum LH | 30–60 min post-injection at day 7 of protocol (timed draw) | >2× pre-injection baseline; typical response +2–6 IU/L above baseline in healthy men |
| Total testosterone | Fasted AM baseline, then day 14 and day 28 | Upward trend vs. baseline; absolute target depends on clinical context |
| FSH | Baseline and day 28 | — |
| Estradiol (E2) | Baseline and day 28, especially during post-TRT restart with HCG co-administration | 20–40 pg/mL male reference range; adjust protocol if estradiol rises disproportionately to testosterone |
Confirms individual KISS1R responsiveness; failure to raise LH ≥2× baseline suggests iHH, axis suppression, or degraded peptide
Primary therapeutic endpoint for hypogonadism and post-TRT recovery protocols
Confirms full gonadotropin axis stimulation; FSH rise confirms pituitary is responding to GnRH output
Rising testosterone will aromatize; monitor for estrogen excess during HPG recovery, particularly when stacking with HCG
After IV or SC injection, plasma kisspeptin levels peak within 10-15 minutes. A measurable rise in serum LH begins within 15-20 minutes. No subjective effects are typically noticed.
Peak LH response occurs at 30-40 minutes post-injection. FSH also rises but with a smaller magnitude. In men, testosterone begins to increase following the LH spike.
LH levels gradually return to baseline by approximately 3 hours. Testosterone elevation persists slightly longer in men. The acute hormonal cascade is complete.
With daily subcutaneous dosing, repeated LH pulses are observed. Some studies show sustained elevation of mean LH levels and increased LH pulse frequency over 1-2 weeks of administration.
Tachyphylaxis may develop with continuous exposure. Pulsatile or intermittent dosing protocols may better maintain responsiveness. Testosterone and gonadotropin changes should be monitored by bloodwork.
Minutes 0 to 30: Plasma kisspeptin-10 levels peak within 10 to 15 minutes after IV dosing, or 20 to 30 minutes subcutaneous. LH begins rising at the 15 to 20 minute mark. Nothing feels different yet. Most users take the injection and go about their evening. Minutes 30 to 90: LH hits its peak at 30 to 40 minutes regardless of injection route. FSH rises too, though with a smaller magnitude. In men, testosterone starts climbing on the back of that LH spike [1]. Some users report a subtle warmth or energy shift in this window. Honestly, that is likely psychosomatic or an early hormonal signal that is hard to separate from placebo. Days 1 to 7 (repeated dosing): Repeated daily LH pulses begin to accumulate. Mean LH and testosterone trend upward over the first 1 to 2 weeks with consistent subcutaneous dosing. Community reports point to improved morning erections, mood, and energy starting around days 5 to 10. Individual response is highly variable; some users notice nothing subjective at all. Occasional headache is the only adverse event documented at community doses. Weeks 2 to 4: The peak benefit window. Maximum testosterone and LH elevation, assuming receptor sensitivity is still intact. Tachyphylaxis risk increases past week 2 with uninterrupted daily dosing. Community users most commonly report improved libido, strength, and general well-being at weeks 3 to 4. Diminishing returns begin if cycling has not been implemented. Reduced LH response on blood draws is the first sign of KISS1R fatigue. Weeks 4 and beyond (off cycle): KISS1R sensitivity recovers during the washout period. Hormonal benefits typically persist for several weeks after discontinuation if the axis has normalized. Most users maintain testosterone gains for 2 to 4 weeks after stopping, then see a gradual taper. The community standard for long-term use is 30 days on, 30 days off, or 4 weeks on, 4 weeks off.
Plasma KP10 peaks ~10–15 min IV / ~20–30 min SC (estimated). LH begins rising within 15–20 min. No subjective effects in this window.
No noticeable effects. Users take injection and continue normal activity.
Peak LH at 30–40 min post-injection regardless of route. FSH rises with smaller magnitude. Testosterone begins rising in men following LH spike (PMID 21632807).
Some users report subtle warmth or energy shift around this window: likely psychosomatic or early testosterone-adjacent.
Repeated LH pulses accumulate. Mean LH and testosterone trend upward over 1–2 weeks with consistent daily SC dosing.
Improved morning erections, mood, and energy beginning days 5–10. Individual response is highly variable; some users report no noticeable change.
Maximum testosterone and LH elevation if receptor sensitivity maintained. Tachyphylaxis risk increases beyond week 2 with uninterrupted daily dosing.
Improved libido, strength, and well-being most commonly reported at 3–4 weeks. Diminishing returns begin if cycling not implemented.
KISS1R sensitivity recovers during washout. Hormonal benefits typically persist for several weeks post-discontinuation if axis has normalized.
Most users maintain testosterone gains for 2–4 weeks after stopping, then gradually taper. 30/30 or 4/4 cycling is community standard for long-term efficacy preservation.
Source: IV terminal half-life of ~4 minutes in humans; subcutaneous administration extends effective duration to ~30 minutes due to slower absorption from the injection depot (PMID 21632807)
Loading the interactive decay curve.
Kisspeptin-10 is classified as a research chemical in the United States. It has no FDA-approved therapeutic indication. The FDA Pharmacy Compounding Advisory Committee voted against including kisspeptin on the bulk drug substances list for compounding in October 2024. This means compounding pharmacies cannot legally prepare kisspeptin-10 prescriptions. Current supply comes exclusively from research peptide vendors selling for "research purposes only, not for human consumption." Quality varies between vendors. Lot-specific certificates of analysis with HPLC purity and mass spectrometry identity confirmation are the minimum standard for evaluating a source. Kisspeptin-10 is not currently listed as a prohibited substance by the World Anti-Doping Agency (WADA), though athletes should verify current prohibited lists before use, as classifications change. Clinical research continues internationally. Kisspeptin-54 (the full-length form) has more advanced clinical trial data, particularly for IVF applications. Intranasal kisspeptin delivery was validated in humans in 2025. This content is for informational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any research peptide.
Peptide Schedule Research TeamReviewed Apr 20269 Citations
